Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including
pulmonary vascular disease and pulmonary fibrosis.
Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic
pulmonary fibrosis (IPF), a condition for which no established treatment is available.
The present trial investigates a possible use of bosentan, which is currently approved for
the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a
new category of patients suffering from IPF.
It was decided to offer Open Label treatment (bosentan) for patients willing to continue in
the BUILD 1 study.